6505--Intent to Sole Source | Xofigo RA-223 | Brand Name Only 5 YR-Indefinite Delivery/Indefinite Quantity (IDIQ) Multiple Stations (646, 642, 595)
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA) has awarded a sole-source, Fixed Price, Indefinite Delivery, Indefinite Quantity (IDIQ) contract to Cardinal Health 414, LLC for the supply of Xofigo (Radium 223 Dichloride injection). This award ensures the continuous provision of this critical radiopharmaceutical for prostate cancer treatment at VA Medical Centers in Lebanon, Pittsburgh, and Philadelphia. The award amount is listed as $0.00.
Scope of Work
This contract covers the delivery and inventory management of brand name Xofigo (Radium 223 dichloride injection 6ml/vial). Xofigo is a unique pharmaceutical used to treat prostate cancer that is resistant to prior medical or surgical treatments and has spread to the patient's bone. The distributor is required to maintain locations within the greater Pittsburgh, Philadelphia, and Lebanon areas due to the short 68-minute half-life of the radiopharmaceutical. The contractor must be licensed by the Nuclear Regulatory Commission and be regularly established in the business of providing Xofigo.
Contract Details
- Contract Type: Fixed Price, Indefinite Delivery, Indefinite Quantity (IDIQ)
- Awardee: CARDINAL HEALTH 414, LLC (UEI: CWN9UGL3NCL9)
- Award Date: March 31, 2026
- Award Amount: $0.00 (Total estimated amount of procurement is redacted in the justification document)
- Period of Performance: April 1, 2026, through March 31, 2031 (5 years)
- Estimated Quantity: 4400 vials per year
- Product Service Code: 6505 (Drugs And Biologicals)
- NAICS Code: 325412
Set-Aside & Justification
This procurement was conducted under Other Than Full and Open Competition as a sole-source award. Market research indicated that Bayer HealthCare Pharmaceuticals, Inc. is the sole manufacturer of Xofigo, and Cardinal Health 414, LLC is its only authorized distributor. A special notice was posted on SAM.gov, and no other interested sources were identified. The VA will continue to monitor the commercial marketplace for potential future competitive opportunities.
Contact Information
- Contract Specialist: Christa Stine
- Email: christa.stine@va.gov
- Phone: 570-824-3521